Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 574

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 574
---
 Diagnostics clinical genetic tests in Argentina. (See Note 2.10 — Trade and other receivables, net) The Group identified a single performance obligation, namely, the delivery of the analysis results to CIBIC. The Group enables CIBIC to include these tests in its service portfolio, with CIBIC responsible to market these tests directly to patients and stakeholders in the healthcare industry, including physicians and healthcare institutions. CIBIC collects patient samples from its medical centers and delivers them to the Group’s laboratory for processing. Once the samples are received and processed, the Group generates reports with the results, which CIBIC then delivers to the patients and physicians. The Group establishes a price for each test, which CIBIC pays per test sold. CIBIC independently determines the retail price at which it sells these tests to end consumers. Revenue generated from selling the tests and other genetics sequencing services is recognized at a point in time when the reports with the results of the tests are sent to CIBIC. F-74

Notes to Combined Financial Statements (Amounts in US Dollars, except otherwise indicated) 2.Summary of significant accounting policies and basis of preparation (cont.) Rewell Segment The Rewell division provides at -homeDNA and microbiome test kits designed to support nutrition -basedhealth risk -managementand promote preventive health strategies through DNA and gut microbiome insights. The Group has identified two performance obligations, namely, the delivery of test results to the customer, and the provision of an upon -demandcomplementary coaching session to review test results and develop an actionable health plan. The transaction price includes the amount of fixed consideration the Group expects to receive. Revenue generated is recognized at a point in time when each performance obligation is satisfied. The transaction price is allocated between the two performance obligations by the amount that represents the portion of the consideration to which the entity expects to be entitled in exchange for transferring the services promised to the customer, based on the relative stand -aloneselling price. 2.5Property, plant and equipment, net Property, plant and equipment assets are measured at historical cost less accumulated depreciation and impairment loss, if any. The cost of property, plant and equipment is the fair value of the consideration initially provided to acquire or construct the item and prepare it for use. Subsequent costs incurred for repair and maintenance are expensed in the statements of comprehensive income unless these costs meet the criteria for capitalization (i.e. extension of the useful life). Depreciation commences when the assets are ready for use.